US Stock MarketDetailed Quotes
ARWR Arrowhead Pharmaceuticals
- 23.170
- +0.550+2.43%
Close May 1 16:00 ET
- 23.170
- 0.0000.00%
Post 16:20 ET
2.87BMarket Cap-8364P/E (TTM)
23.840High22.660Low1.11MVolume22.720Open22.620Pre Close25.83MTurnover0.94%Turnover RatioLossP/E (Static)123.90MShares41.36052wk High17.89P/B2.76BFloat Cap20.67052wk Low--Dividend TTM118.95MShs Float162.500Historical High--Div YieldTTM5.22%Amplitude1.200Historical Low23.195Avg Price1Lot Size
Arrowhead Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | (Q2)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -56.05%-117.84M | -13.05%-153.89M | 63.26%-25.26M | 68.84%-21.45M | -150.49%-31.67M | -23.17%-75.52M | -179.46%-136.13M | -186.06%-68.74M | -132.40%-68.82M | -76.23%62.73M |
| Net income from continuing operations | -223.78%-135.38M | -18.57%-209.28M | -29.17%-111.02M | -44.53%-104.13M | 7.46%47.68M | 33.50%-41.81M | -25.31%-176.49M | -35.61%-85.94M | -140.76%-72.05M | 265.43%44.37M |
| Operating gains losses | ---80K | ---- | ---- | ---- | ---- | ---- | 359.48%4.43M | ---- | ---- | ---- |
| Depreciation and amortization | 58.53%4.26M | 19.88%12.49M | 45.08%3.86M | 26.29%3.28M | 2.89%2.67M | 4.51%2.69M | 26.06%10.42M | 6.23%2.66M | 29.89%2.59M | 35.25%2.59M |
| Other non cash items | 88.38%5.37M | --18.33M | --6.29M | 150.00%4.21M | 716.91%4.98M | 1,117.50%2.85M | ---- | ---- | 3,401.96%1.68M | 23.03%609K |
| Change In working capital | 81.67%-10.87M | 47.56%-51.55M | 517.88%59.44M | 237.46%55.25M | -473.48%-106.91M | -135.10%-59.32M | -142.99%-98.29M | -688.78%-14.23M | -105.41%-40.19M | -106.81%-18.64M |
| -Change in receivables | --0 | -84.06%1.41M | 206.40%1.25M | 6,225.42%68.19M | -2,459.30%-29.87M | -477.61%-38.16M | 194.01%8.85M | 87.78%-1.17M | 280.92%1.08M | -114.50%-1.17M |
| -Change in prepaid assets | -116.60%-1.75M | 160.15%11.6M | -56.47%-16.31M | 236.91%7.6M | 441.60%9.78M | 2,439.78%10.53M | -5,258.61%-19.29M | -511.20%-10.42M | -714.37%-5.55M | -392.14%-2.86M |
| -Change in payables and accrued expense | -29.97%-12.06M | 61.57%18.03M | 246.74%45.11M | 3.06%-6.49M | -190.35%-11.32M | -20.78%-9.28M | -8.14%11.16M | 374.49%13.01M | -141.46%-6.7M | 223.70%12.52M |
| -Change in other current liabilities | 579.07%3.8M | ---- | ---- | ---- | 84.57%646K | 143.04%559K | ---- | ---- | ---- | --350K |
| -Change in other working capital | 96.23%-866K | 16.58%-82.59M | 287.92%29.39M | 54.82%-12.85M | -177.06%-76.16M | 16.25%-22.98M | -143.75%-99.01M | -210.12%-15.64M | 19.47%-28.44M | -110.54%-27.49M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -56.05%-117.84M | -13.05%-153.89M | 63.26%-25.26M | 68.84%-21.45M | -150.49%-31.67M | -23.17%-75.52M | -179.46%-136.13M | -186.06%-68.74M | -132.40%-68.82M | -76.23%62.73M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 180.35%64.84M | -1,675.06%-96.16M | -16.29%30.51M | -116.16%-9.91M | 48.30%-36.07M | -141.71%-80.69M | 96.18%-5.42M | 130.82%36.45M | 413.59%61.28M | -104.86%-69.76M |
| Net PPE purchase and sale | -76.44%-68.66M | -234.88%-176.74M | -95.37%-63.91M | -388.73%-46.61M | -474.79%-27.31M | -573.43%-38.91M | -123.94%-52.78M | -298.96%-32.71M | -142.58%-9.54M | 33.69%-4.75M |
| Net investment purchase and sale | 419.50%133.5M | 70.15%80.58M | 36.53%94.42M | -48.17%36.7M | 86.54%-8.75M | -51.35%-41.78M | 140.10%47.36M | 162.84%69.16M | 553.65%70.81M | -141.79%-65M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 180.35%64.84M | -1,675.06%-96.16M | -16.29%30.51M | -116.16%-9.91M | 48.30%-36.07M | -141.71%-80.69M | 96.18%-5.42M | 130.82%36.45M | 413.59%61.28M | -104.86%-69.76M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.89%267K | 288.20%253.05M | -82.22%152K | -97.02%1.81M | -71.83%520K | 13,193.16%250.58M | 476.61%65.19M | 4.91%855K | 2,099.64%60.6M | -29.89%1.85M |
| Proceeds from stock option exercised by employees | -53.65%267K | -41.13%3.05M | -3.98%821K | 89.33%1.14M | -71.83%520K | -69.44%576K | -54.13%5.19M | 4.91%855K | -78.22%600K | -29.89%1.85M |
| Net other financing activities | ---- | 316.67%250M | ---669K | --669K | --0 | --250M | --60M | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.89%267K | 288.20%253.05M | -82.22%152K | -97.02%1.81M | -71.83%520K | 13,193.16%250.58M | 476.61%65.19M | 4.91%855K | 2,099.64%60.6M | -29.89%1.85M |
| Net cash flow | ||||||||||
| Beginning cash position | 2.67%110.89M | -41.44%108.01M | -24.46%105.33M | 56.19%134.96M | 120.83%202.25M | -41.44%108.01M | 28.45%184.43M | -57.22%139.44M | -76.80%86.41M | -34.54%91.59M |
| Current changes in cash | -155.88%-52.73M | 103.94%3.01M | 117.19%5.4M | -155.68%-29.55M | -1,197.61%-67.22M | 201.68%94.37M | -286.53%-76.36M | 77.78%-31.44M | 214.37%53.06M | -102.23%-5.18M |
| Effect of exchange rate changes | 147.54%58K | -82.09%-122K | 5,000.00%153K | -146.88%-79K | -7,500.00%-74K | -212.82%-122K | 23.86%-67K | --3K | ---32K | --1K |
| End cash Position | -71.22%58.22M | 2.67%110.89M | 2.67%110.89M | -24.46%105.33M | 56.19%134.96M | 120.83%202.25M | -41.44%108.01M | -41.44%108.01M | -57.22%139.44M | -76.80%86.41M |
| Free cash flow | -62.98%-186.5M | -75.02%-330.63M | 12.11%-89.16M | 13.15%-68.05M | -201.74%-58.99M | -70.57%-114.43M | -227.86%-188.91M | -214.78%-101.45M | -133.60%-78.35M | -77.42%57.98M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg